Results 31 to 40 of about 3,958 (169)

Stimulation of Erythrocyte Cell Membrane Scrambling by Mitotane

Cellular Physiology and Biochemistry, 2014
Background: Mitotane (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]ethane), a cytostatic drug used for the treatment of adrenocortical carcinomas, is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, eryptosis
Janin Jacobi, Elisabeth Lang, Rosi Bissinger, Leonie Frauenfeld, Paola Modicano, Caterina Faggio, Majed Abed, Florian Lang   +7 more
doaj   +1 more source

Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)

Xiehe Yixue Zazhi, 2021
Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex, and surgery is the first choice for treating ACC. Medical therapy and radiotherapy are adjuvant treatments for patients with unresectable metastasized tumors or ...
Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital
doaj   +1 more source

Liver X receptor inhibition potentiates mitotane induced adrenotoxicity in ACC [PDF]

, 2020
Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with a poor outcome largely due to limited treatment options. Here, we propose a novel therapeutic approach through modulating intracellular free cholesterol via the liver X receptor alpha ...
Chatterjee, Krishna V., Ribes Martinez, Eduardo, Schoenmakers, Erik, Lawless, Sarah J, Lawless, Sarah J., Lim, Yi Jan, Warde, Kate M, O'Shea, Paula, Martinez, Eduardo Ribes, Gurnell, Mark, Hantel, Constanze, Chatterjee, Krishna V, Dennedy, Michael Conall, Schoenmakers, Erik; id_orcid, Leonard, Maeve, Warde, Kate M., aO Shea, Paula   +16 more
core   +4 more sources

Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report

International Journal of Translational Medicine
Background: Mitotane is the cornerstone adjuvant and palliative treatment for adrenocortical carcinoma (ACC), requiring strict therapeutic drug monitoring (TDM) due to its narrow therapeutic window and high inter- and intra-individual pharmacokinetic ...
Sonia Fernández-Cañabate, Asunción Díaz-Serrano, Álvaro Corral-Alaejos   +2 more
doaj   +1 more source

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Endocrine Oncology, 2023
Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer.
Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra   +2 more
doaj   +1 more source

Bioactivation mechanisms for mitotane and its analogs.

, 1993
Mitotane ($o,p\sp\prime$-DDD, 1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,$2$ -dichloroethane) is the only drug currently available that has extended survival in patients with adrenocortical carcinoma.
Cai, Wei
core   +7 more sources

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma

Endocrine Connections
Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex. Whilst surgery is the preferred treatment, adjunctive therapy with mitotane may be offered post-surgically to minimise the risk of recurrence or, in the absence of ...
Magdalena Lech, Ruvini Ranasinghe, Royce P Vincent, David R Taylor, Lea Ghataore, James Luxton, Fannie Lajeunesse-Trempe, Pia Roser, Eftychia E Drakou, Ling Ling Chuah, Ashley B Grossman, Simon J B Aylwin, Georgios K Dimitriadis   +12 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report

Pediatric Hematology Oncology Journal
Background: Mitotane is employed as adjuvant therapy in managing adrenocortical carcinoma in pediatric patients. While various adverse effects, such as estrogen-like manifestations, are well-documented in adults, there is limited knowledge regarding ...
Maria Riedmeier, Sonir Antonini, Clemens Benoit, Cheri L. Deal, Fassnacht Martin, Bonald C. Figueiredo, Elmas Nazli Gonc, Christoph Härtel, Jan Idkowiak, Max Kurlbaum, Ronald de Krijger, Raul C. Ribeiro, Jaydira del Rivero, Paul-Gerhardt Schlegel, Lester D.R. Thompson, Bilgehan Yalcin, Verena Wiegering   +16 more
doaj   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source